

# B F Chong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577557/publications.pdf>

Version: 2024-02-01

79  
papers

1,303  
citations

430874

18  
h-index

414414

32  
g-index

79  
all docs

79  
docs citations

79  
times ranked

1814  
citing authors

#	ARTICLE	IF	CITATIONS
1	Decreased progression to systemic lupus erythematosus in patients with cutaneous lupus erythematosus under European League Against Rheumatism/American College of Rheumatology criteria. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 187-190.	1.2	4
2	A cross-sectional study of no-show rates and factors contributing to nonattendance at 3 academic pediatric dermatology centers in the United States. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1169-1172.	1.2	6
3	Cost minimization analysis of mainstay treatments in cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , 2022, 35, e15190.	1.7	4
4	SnapshotDx Quiz: February 2022. <i>Journal of Investigative Dermatology</i> , 2022, 142, e15-e20.	0.7	0
5	Discoid lesions and smoking history are negative predictors of disease activity remission in cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1135-1137.	1.2	2
6	Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy. <i>Journal of Investigative Dermatology</i> , 2022, 142, 936-943.	0.7	3
7	A Systematic Review of the Progression of Cutaneous Lupus to Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2022, 13, 866319.	4.8	11
8	Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 559-566.	1.2	3
9	Classification of Disease Damage and Activity in Cutaneous Lupus Erythematosus: A Cross-Sectional Analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	1.2	0
10	Worsening skin damage in patients with cutaneous lupus erythematosus may predict development of systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 538-540.	1.2	4
11	SnapshotDx Quiz: February 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e15-e19.	0.7	0
12	Modular gene analysis reveals distinct molecular signatures for subsets of patients with cutaneous lupus erythematosus*. <i>British Journal of Dermatology</i> , 2021, 185, 563-572.	1.5	9
13	Differences in quality of life in patients with cutaneous lupus erythematosus with varying income levels. <i>Lupus</i> , 2021, 30, 972-980.	1.6	6
14	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 431-431.	1.7	15
15	Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus. <i>Annals of Translational Medicine</i> , 2021, 9, 429-429.	1.7	11
16	Treatments for disease damage in cutaneous lupus erythematosus: A narrative review. <i>Dermatologic Therapy</i> , 2021, 34, e15034.	1.7	5
17	Development of systemic lupus in patients with cutaneous lupus using the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 200-202.	1.2	7
18	Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine. <i>Dermatologic Therapy</i> , 2021, 34, e15114.	1.7	26

#	ARTICLE	IF	CITATIONS
19	Guidance for providers on the treatment and management of cutaneous lupus erythematosus. British Journal of Dermatology, 2021, , .	1.5	0
20	Elevated serum levels of C-X-C motif chemokine ligand 10 can distinguish systemic lupus erythematosus patients from cutaneous lupus erythematosus patients. Journal of the American Academy of Dermatology, 2021, 85, 1051-1054.	1.2	1
21	Evaluation of the effect of store-and-forward teledermatology on in-person health care system utilization in a safety-net public health and hospital system. Journal of the American Academy of Dermatology, 2021, 85, 1026-1028.	1.2	2
22	Non-adherence of surgical treatment in patients with non-melanoma skin cancer: a retrospective cohort pilot study. Archives of Dermatological Research, 2021, , 1.	1.9	0
23	Discoid lupus erythematosus skin lesion distribution and characteristics in Black patients: a retrospective cohort study. Lupus Science and Medicine, 2021, 8, e000514.	2.7	13
24	Developing classification criteria for skinâ€predominant dermatomyositis: the Delphi process. British Journal of Dermatology, 2020, 182, 410-417.	1.5	25
25	Tâ€cell polarization differs in various stages of discoid lupus erythematosus skin. British Journal of Dermatology, 2020, 182, 1291-1293.	1.5	3
26	Autoimmune disease development before and after cutaneous lupus erythematosus diagnosis. British Journal of Dermatology, 2020, 182, 1309-1310.	1.5	3
27	Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model. Lupus, 2020, 29, 1691-1703.	1.6	7
28	SnapshotDx Quiz: October 2020. Journal of Investigative Dermatology, 2020, 140, e109-e113.	0.7	0
29	SnapshotDx Quiz: June 2020. Journal of Investigative Dermatology, 2020, 140, e61-e64.	0.7	0
30	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. JAMA Dermatology, 2020, 156, 901.	4.1	18
31	Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed <sc>COVID</sc> â€19. Dermatologic Therapy, 2020, 33, e13834.	1.7	14
32	Principal components analysis as a tool to identify lesional skin patterns in cutaneous lupus erythematosus. Journal of the American Academy of Dermatology, 2020, 83, 922-924.	1.2	2
33	Exclusion of Cutaneous Lupus Erythematosus Subtypes From the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus: Comment on the Article by Aringer et al. Arthritis and Rheumatology, 2020, 72, 1403-1404.	5.6	7
34	Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus. Lupus Science and Medicine, 2020, 7, e000364.	2.7	1
35	Practiceâ€based differences in paediatric discoid lupus erythematosus. British Journal of Dermatology, 2019, 181, 805-810.	1.5	8
36	Expansion of Myeloid-Derived Suppressor Cells in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients. Journal of Investigative Dermatology, 2019, 139, 478-481.	0.7	15

#	ARTICLE	IF	CITATIONS
37	Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2019, 180, 1430-1437.	1.5	17
38	Applying the Cutaneous Lupus Erythematosus Disease Area and Severity Index to paediatric cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2019, 180, 20-21.	1.5	0
39	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus "An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , 2019, 139, 270-276.	0.7	18
40	Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial. <i>Arthritis Care and Research</i> , 2019, 71, 1425-1429.	3.4	2
41	Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis. <i>Nature Medicine</i> , 2018, 24, 617-627.	30.7	117
42	Ulcerative livedoid vasculopathy responding to clopidogrel. <i>JAAD Case Reports</i> , 2018, 4, 203-205.	0.8	2
43	SnapshotDx Quiz: February 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e19.	0.7	0
44	Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. <i>JAMA Dermatology</i> , 2018, 154, 712.	4.1	9
45	2456 Cutaneous lupus erythematosus patients have increased circulating myeloid-derived suppressor cells with immunosuppressive properties. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 7-8.	0.6	0
46	Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 694.	1.6	25
47	SnapshotDx Quiz: June 2018. <i>Journal of Investigative Dermatology</i> , 2018, 138, e43.	0.7	0
48	Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study. <i>International Journal of Women's Dermatology</i> , 2018, 4, 152-158.	2.0	21
49	Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1053-1060.e3.	1.2	12
50	Outcomes associated with shorter wait times at a county hospital outpatient dermatology clinic. <i>Cutis</i> , 2018, 102, 159-160.	0.3	1
51	Changes in T cell and B cell composition in discoid lupus erythematosus skin at different stages. <i>Journal of Dermatological Science</i> , 2017, 85, 247-249.	1.9	22
52	Patient-reported outcomes in patients with cutaneous lupus. <i>British Journal of Dermatology</i> , 2017, 176, 7-7.	1.5	0
53	Creation of an Internal Teledermatology Store-and-Forward System in an Existing Electronic Health Record. <i>JAMA Dermatology</i> , 2017, 153, 644.	4.1	47
54	Predictors of low quality of life in patients with discoid lupus. <i>British Journal of Dermatology</i> , 2017, 177, e147-e149.	1.5	9

#	ARTICLE	IF	CITATIONS
55	Not Just Skin Deep: Systemic Disease Involvement in Patients With Cutaneous Lupus. Journal of Investigative Dermatology Symposium Proceedings, 2017, 18, S69-S74.	0.8	11
56	Assessment of dermatology clinic resources at safety-net hospitals: Results from a national survey. Journal of the American Academy of Dermatology, 2017, 77, 977-978.e2.	1.2	3
57	Pathogenesis of morphoea: knowledge gaps in subtypes and comparisons to systemic sclerosis. British Journal of Dermatology, 2017, 177, 9-10.	1.5	0
58	Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell Suppressor Mechanisms. Journal of Investigative Dermatology, 2016, 136, 1801-1810.	0.7	38
59	Reducing outpatient dermatology clinic wait times in a safety net health system in Dallas, Texas. Journal of the American Academy of Dermatology, 2016, 75, 631-632.	1.2	6
60	Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clinical Immunology, 2016, 169, 58-68.	3.2	61
61	A subset of CD163+ macrophages displays mixed polarizations in discoid lupus skin. Arthritis Research and Therapy, 2015, 17, 324.	3.5	40
62	Sunscreen use in patients with cutaneous lupus erythematosus. British Journal of Dermatology, 2015, 173, 831-834.	1.5	15
63	Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus. JAMA Dermatology, 2015, 151, 539.	4.1	16
64	IgG, IgM, and IgA Antinuclear Antibodies in Discoid and Systemic Lupus Erythematosus Patients. Scientific World Journal, The, 2014, 2014, 1-7.	2.1	26
65	Site-Specific Analysis of Inflammatory Markers in Discoid Lupus Erythematosus Skin. Scientific World Journal, The, 2014, 2014, 1-12.	2.1	17
66	Autoantibodies and Disease Activity in Patients With Discoid Lupus Erythematosus. JAMA Dermatology, 2014, 150, 651.	4.1	10
67	Understanding How Cutaneous Lupus Erythematosus Progresses to Systemic Lupus Erythematosus. JAMA Dermatology, 2014, 150, 296.	4.1	13
68	Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. Journal of Dermatological Science, 2014, 73, 216-224.	1.9	40
69	A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. British Journal of Dermatology, 2013, 168, 145-153.	1.5	50
70	Photosensitivity in cutaneous lupus erythematosus. Photodermatology Photoimmunology and Photomedicine, 2013, 29, 4-11.	1.5	50
71	Photoprotective habits of patients with cutaneous lupus erythematosus. Journal of the American Academy of Dermatology, 2013, 68, 944-951.e1.	1.2	17
72	IgG and IgM Autoantibody Differences in Discoid and Systemic Lupus Patients. Journal of Investigative Dermatology, 2012, 132, 2770-2779.	0.7	32

#	ARTICLE	IF	CITATIONS
73	Autoantibody and Clinical Profiles in Patients With Discoid Lupus and Borderline Systemic Lupus. Archives of Dermatology, 2012, 148, 651-5.	1.4	8
74	Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. British Journal of Dermatology, 2012, 166, 29-35.	1.5	93
75	25-Hydroxyvitamin D levels in African-American and Caucasian/Hispanic subjects with cutaneous lupus erythematosus. British Journal of Dermatology, 2012, 166, 372-379.	1.5	20
76	Risk factors for ANA positivity in healthy persons. Arthritis Research and Therapy, 2011, 13, R38.	3.5	136
77	Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets, 2009, 13, 1147-1153.	3.4	61
78	The Genetic Landscape of Cutaneous Lupus Erythematosus. Frontiers in Medicine, 0, 9, .	2.6	2
79	Influence of Socio-Demographic Factors in Patients With Cutaneous Lupus Erythematosus. Frontiers in Medicine, 0, 9, .	2.6	1